Kress B C, Mizrahi I A, Armour K W, Marcus R, Emkey R D, Santora A C
Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc., San Diego, CA 92196, USA.
Clin Chem. 1999 Jul;45(7):1009-17.
Biochemical bone markers are sensitive to the changes in bone turnover that result from treatment of postmenopausal osteoporotic women with antiresorptive therapies. Although information is available on the use of bone markers in monitoring therapy in groups of subjects, less is known regarding how these markers perform in individual patients.
Serum bone alkaline phosphatase (bone ALP) concentrations, measured with the Tandem(R) Ostase(R) assay, were used to monitor the biochemical response of bone in postmenopausal women with osteoporosis receiving either 10 mg/day alendronate therapy (n = 74) or calcium supplementation (n = 148) for 24 months.
Bone ALP decreased significantly from baseline at 3 months (P </=0.0001), reaching a nadir between 3 and 6 months of alendronate therapy. The magnitude of the bone ALP decrease in the treated osteoporotic population was consistent with normalization to premenopausal concentrations. Of the 74 alendronate-treated subjects, 63 (85.1%) demonstrated a decrease from baseline in bone ALP by 6 months that exceeded the least significant change of 25%. The bone ALP decrease from baseline exceeded 25% in 72 (97%) by the end of the study.
The bone ALP assay is a sensitive and reliable tool that may be used to monitor the reduction in bone turnover after alendronate therapy in individual postmenopausal osteoporotic women.
生化骨标志物对绝经后骨质疏松症女性采用抗吸收疗法治疗所导致的骨转换变化敏感。尽管已有关于骨标志物在受试者群体治疗监测中应用的信息，但对于这些标志物在个体患者中的表现了解较少。
采用Tandem® Ostase® 检测法测定血清骨碱性磷酸酶（骨ALP）浓度，以监测接受10毫克/天阿仑膦酸盐治疗（n = 74）或补充钙剂（n = 148）24个月的绝经后骨质疏松症女性的骨生化反应。
骨ALP在3个月时较基线水平显著下降（P≤0.0001），在阿仑膦酸盐治疗3至6个月时降至最低点。治疗的骨质疏松症人群中骨ALP下降幅度与恢复至绝经前浓度一致。在74名接受阿仑膦酸盐治疗的受试者中，63名（85.1%）在6个月时骨ALP较基线水平下降超过最小显著变化25%。到研究结束时，72名（97%）受试者的骨ALP较基线水平下降超过25%。
骨ALP检测是一种敏感且可靠的工具，可用于监测个体绝经后骨质疏松症女性接受阿仑膦酸盐治疗后骨转换的降低情况。
